AlzeCure Pharma Management
Management criteria checks 3/4
AlzeCure Pharma's CEO is Martin Jönsson, appointed in Jan 2020, has a tenure of 4.58 years. total yearly compensation is SEK2.48M, comprised of 76.6% salary and 23.4% bonuses, including company stock and options. directly owns 0.46% of the company’s shares, worth SEK759.56K. The average tenure of the management team and the board of directors is 4.6 years and 3.3 years respectively.
Key information
Martin Jönsson
Chief executive officer
SEK 2.5m
Total compensation
| CEO salary percentage | 76.6% |
| CEO tenure | 4.6yrs |
| CEO ownership | 0.5% |
| Management average tenure | 4.6yrs |
| Board average tenure | 3.3yrs |
Recent management updates
Recent updates
We Think AlzeCure Pharma (STO:ALZCUR) Can Afford To Drive Business Growth
Dec 02
Companies Like AlzeCure Pharma (STO:ALZCUR) Can Afford To Invest In Growth
Jul 20Will AlzeCure Pharma (STO:ALZCUR) Spend Its Cash Wisely?
Oct 12Is AlzeCure Pharma (STO:ALZCUR) In A Good Position To Invest In Growth?
Jan 03Is AlzeCure Pharma (STO:ALZCUR) In A Good Position To Invest In Growth?
Jul 12Is AlzeCure Pharma (STO:ALZCUR) In A Good Position To Invest In Growth?
Mar 28Need To Know: AlzeCure Pharma AB (publ) (STO:ALZCUR) Insiders Have Been Buying Shares
Feb 03We're Not Very Worried About AlzeCure Pharma's (STO:ALZCUR) Cash Burn Rate
Dec 13CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Mar 31 2024 | n/a | n/a | -SEK 37m |
| Dec 31 2023 | SEK 2m | SEK 2m | -SEK 37m |
| Sep 30 2023 | n/a | n/a | -SEK 38m |
| Jun 30 2023 | n/a | n/a | -SEK 42m |
| Mar 31 2023 | n/a | n/a | -SEK 53m |
| Dec 31 2022 | SEK 2m | SEK 2m | -SEK 56m |
| Sep 30 2022 | n/a | n/a | -SEK 68m |
| Jun 30 2022 | n/a | n/a | -SEK 73m |
| Mar 31 2022 | n/a | n/a | -SEK 67m |
| Dec 31 2021 | SEK 2m | SEK 2m | -SEK 78m |
| Sep 30 2021 | n/a | n/a | -SEK 73m |
| Jun 30 2021 | n/a | n/a | -SEK 78m |
| Mar 31 2021 | n/a | n/a | -SEK 81m |
| Dec 31 2020 | SEK 2m | SEK 1m | -SEK 71m |
Compensation vs Market: Martin's total compensation ($USD234.03K) is about average for companies of similar size in the Swedish market ($USD284.09K).
Compensation vs Earnings: Martin's compensation has increased whilst the company is unprofitable.
CEO
Martin Jönsson (56 yo)
4.6yrs
Tenure
SEK 2,475,000
Compensation
Mr. Martin Jönsson is the Chief Executive Officer of AlzeCure Pharma AB (publ) since January 8, 2020. Mr. Jönsson served in a senior position at Ferring Pharmaceuticals in the US, he was business area dire...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chief Executive Officer | 4.6yrs | SEK 2.48m | 0.46% SEK 759.6k | |
| Chief Financial Officer | 7.6yrs | no data | 0.14% SEK 227.2k | |
| Chief Scientific Officer | 4.6yrs | SEK 1.28m | 0.99% SEK 1.6m | |
| Chief Medical Officer & Head of Development | 3.3yrs | no data | 0.084% SEK 137.6k | |
| Head of Research & Discovery | 7.6yrs | no data | 1.03% SEK 1.7m |
4.6yrs
Average Tenure
57yo
Average Age
Experienced Management: ALZCUR's management team is considered experienced (4.6 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman | 7.6yrs | SEK 229.00k | 1.7% SEK 2.8m | |
| Director | less than a year | no data | no data | |
| Independent Director | 7.6yrs | SEK 115.00k | 0.056% SEK 92.2k | |
| Scientific Advisor | no data | no data | no data | |
| Scientific Advisor | no data | no data | no data | |
| Scientific Advisor | no data | no data | no data | |
| Scientific Advisor | no data | no data | no data | |
| Scientific Advisor | no data | no data | no data | |
| Independent Director | 1.3yrs | SEK 73.00k | 0.028% SEK 46.4k | |
| Scientific Advisor | no data | no data | no data | |
| Independent Director | 3.3yrs | SEK 115.00k | 0.0028% SEK 4.6k |
3.3yrs
Average Tenure
70yo
Average Age
Experienced Board: ALZCUR's board of directors are considered experienced (3.3 years average tenure).